704 Biological activity of FLX475, an oral CCR4 antagonist, as monotherapy and in combination with pembrolizumab in advanced cancer
Main Authors: | Qingfeng Zhu, Robert Anders, Damian Trujillo, Dirk G Brockstedt, Michael Chisamore, Juraj Adamik, Paul D Kassner, William Ho, Rakesh Kumar Goyal, Adam Grant, Shoji Ikeda, Marvin Au, Denise Nagata, Eugene Lurie, Mohsen Sabouri Ghomi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
629-C Phase 2 safety and efficacy of oral CCR4 antagonist FLX475 (tivumecirnon) plus pembrolizumab in subjects with non-small cell lung cancer not previously treated with checkpoint inhibitor
by: Jameel Muzaffar, et al.
Published: (2023-11-01) -
Periprocedural outcome in patients undergoing left atrial appendage occlusion with the Watchman FLX device: The ITALIAN-FLX registry
by: Sergio Berti, et al.
Published: (2023-04-01) -
Watchman FLX's Sophomore Year Report Card
by: Thomas A. Dewland
Published: (2023-02-01) -
1240 Safety profile of pembrolizumab monotherapy versus pembrolizumab with combined treatments: analysis of french pharmacovigilance database
by: Laure Thomas, et al.
Published: (2023-11-01) -
Circumflex to Left Atrial Appendage Fistula Associated With Watchman FLX Closure Device
by: Stefan Milutinovic, MD, et al.
Published: (2024-02-01)